2,970 Shares in Bristol-Myers Squibb Co (BMY) Acquired by Selective Wealth Management

Selective Wealth Management acquired a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,970 shares of the biopharmaceutical company’s stock, valued at approximately $184,000. Bristol-Myers Squibb makes up approximately 2.2% of Selective Wealth Management’s portfolio, making the stock its 15th biggest position.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CSat Investment Advisory L.P. bought a new stake in shares of Bristol-Myers Squibb during the second quarter valued at approximately $113,000. Landaas & Co. WI ADV bought a new stake in shares of Bristol-Myers Squibb during the second quarter valued at approximately $131,000. Mount Yale Investment Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the first quarter valued at approximately $179,000. LFA Lugano Financial Advisors SA increased its holdings in shares of Bristol-Myers Squibb by 85.8% during the third quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock valued at $199,000 after acquiring an additional 1,481 shares in the last quarter. Finally, Pure Financial Advisors Inc. bought a new stake in shares of Bristol-Myers Squibb during the third quarter valued at approximately $201,000. Hedge funds and other institutional investors own 72.28% of the company’s stock.

BMY stock opened at $57.51 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.28 and a current ratio of 1.40. Bristol-Myers Squibb Co has a 1-year low of $49.96 and a 1-year high of $70.05. The firm has a market capitalization of $101.47 billion, a price-to-earnings ratio of 19.11, a price-to-earnings-growth ratio of 1.70 and a beta of 0.98.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. The business had revenue of $5.70 billion for the quarter, compared to analysts’ expectations of $5.48 billion. During the same quarter in the previous year, the firm earned $0.74 earnings per share. The business’s revenue was up 10.9% on a year-over-year basis. As a group, research analysts predict that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Friday, October 5th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, October 4th. This represents a $1.60 annualized dividend and a yield of 2.78%. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.

Several research analysts recently issued reports on the company. Jefferies Financial Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Sunday, July 15th. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, July 14th. Atlantic Securities raised Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 target price on the stock in a research report on Wednesday, August 8th. Credit Suisse Group reaffirmed a “hold” rating and set a $61.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, September 12th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $47.00 target price on shares of Bristol-Myers Squibb in a research report on Thursday, June 21st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $62.95.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Recommended Story: S&P 500 Index

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply